Basaran D, Bruce S, Aviki EM, et al. - Researchers performed this retrospective review of patients with uterine serous carcinoma (USC) undergoing primary surgical treatment, to evaluate survival in those undergoing sentinel lymph node (SLN) mapping alone vs those undergoing systematic lymphadenectomy (LND). This analysis included 245 patients: SLN group had 79 (32.2%) patients and the LND group had 166 (67.7%). The SLN and LND cohorts were observed over a median duration of 23 (range, 1–96) and 66 months (range, 4–265), respectively. They noted that 96.6% and 89.6% were the two-year overall survival (OS) in stage I/II disease (n = 160, 60.1%) in the SLN and LND cohorts, respectively. In stage III disease (n = 77), the two-year OS was estimated to be 73.6% in the SLN cohort and 77.3% in the LND cohort. Findings revealed that similar survival outcomes in stage I-III USC were provided by SLN mapping alone and systematic LND. In this setting, systematic LND has been substituted by the SLN algorithm as the primary staging modality.